Literature DB >> 23263886

Urokinase-type plasminogen activator receptor modulates epileptogenesis in mouse model of temporal lobe epilepsy.

Xavier Ekolle Ndode-Ekane1, Asla Pitkänen.   

Abstract

Mutation in Plaur gene encoding urokinase-type plasminogen activator receptor (uPAR) results in epilepsy and autistic phenotype in mice. In humans, a single nucleotide polymorphism in PLAUR gene represents a risk for autism spectrum disorders. Importantly, the expression of uPAR is elevated in the brain after various epileptogenic insults like traumatic brain injury and status epilepticus. So far, the consequences of altered uPAR expression on brain networks are poorly known. We tested a hypothesis that uPAR regulates post-injury neuronal reorganization and consequent functional outcome, particularly epileptogenesis. Epileptogenesis was induced by intrahippocampal injection of kainate in adult male wild type (Wt) or uPAR knockout (uPAR-/-) mice, and animals were monitored with continuous (24/7) video-electroencephalogram for 30 days. The severity of status epilepticus did not differ between the genotypes. The spontaneous electrographic seizures which developed were, however, longer and their behavioral manifestations were more severe in uPAR-/- than Wt mice. The more severe epilepsy phenotype in uPAR-/- mice was associated with delayed but augmented inflammatory response and more severe neurodegeneration in the hippocampus. Also, the distribution of newly born cells in the dentate gyrus was more scattered, and the recovery of hippocampal blood vessel length from status epilepticus-induced damage was compromised in uPAR-/- mice as compared to Wt mice. Our data demonstrate that a deficiency in uPAR represents a mechanisms which results in the development of a more severe epilepsy phenotype and progressive brain pathology after status epilepticus. We suggest that uPAR represents a rational target for disease-modifying treatments after epileptogenic brain insults.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23263886     DOI: 10.1007/s12035-012-8386-2

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  62 in total

1.  Inhibition of urokinase-type plasminogen activator receptor induces apoptosis in melanoma cells by activation of p53.

Authors:  R Besch; C Berking; C Kammerbauer; K Degitz
Journal:  Cell Death Differ       Date:  2006-11-17       Impact factor: 15.828

2.  Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator.

Authors:  T H Bugge; M J Flick; M J Danton; C C Daugherty; J Romer; K Dano; P Carmeliet; D Collen; J L Degen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

3.  The murine receptor for urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodeling.

Authors:  H Solberg; M Ploug; G Høyer-Hansen; B S Nielsen; L R Lund
Journal:  J Histochem Cytochem       Date:  2001-02       Impact factor: 2.479

4.  Septotemporal position in the hippocampal formation determines epileptic and neurogenic activity in temporal lobe epilepsy.

Authors:  Ute Häussler; Lena Bielefeld; Ulrich P Froriep; Jakob Wolfart; Carola A Haas
Journal:  Cereb Cortex       Date:  2011-05-13       Impact factor: 5.357

5.  Antigen-driven lymphocyte recruitment to the lung is diminished in the absence of urokinase-type plasminogen activator (uPA) receptor, but is independent of uPA.

Authors:  M R Gyetko; S Sud; J Sonstein; T Polak; A Sud; J L Curtis
Journal:  J Immunol       Date:  2001-11-15       Impact factor: 5.422

6.  Lesion-associated accumulation of uPAR/CD87- expressing infiltrating granulocytes, activated microglial cells/macrophages and upregulation by endothelial cells following TBI and FCI in humans.

Authors:  R Beschorner; H J Schluesener; T D Nguyen; V Magdolen; T Luther; I Pedal; R Mattern; R Meyermann; J M Schwab
Journal:  Neuropathol Appl Neurobiol       Date:  2000-12       Impact factor: 8.090

7.  Hepatocyte growth factor/scatter factor is a motogen for interneurons migrating from the ventral to dorsal telencephalon.

Authors:  E M Powell; W M Mars; P Levitt
Journal:  Neuron       Date:  2001-04       Impact factor: 17.173

8.  The urokinase receptor is required for human monocyte chemotaxis in vitro.

Authors:  M R Gyetko; R F Todd; C C Wilkinson; R G Sitrin
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

9.  Species-specific urokinase receptor ligands reduce glioma growth and increase survival primarily by an antiangiogenesis mechanism.

Authors:  Xingyao Bu; Vazgen Khankaldyyan; Ignacio Gonzales-Gomez; Susan Groshen; Wei Ye; Shaoqiu Zhuo; Jaume Pons; Jennifer R Stratton; Steven Rosenberg; Walter E Laug
Journal:  Lab Invest       Date:  2004-06       Impact factor: 5.662

10.  Epilepsy in autism: features and correlates.

Authors:  Patrick F Bolton; Iris Carcani-Rathwell; Jane Hutton; Sue Goode; Patricia Howlin; Michael Rutter
Journal:  Br J Psychiatry       Date:  2011-04       Impact factor: 9.319

View more
  4 in total

Review 1.  The relevance of inter- and intrastrain differences in mice and rats and their implications for models of seizures and epilepsy.

Authors:  Wolfgang Löscher; Russell J Ferland; Thomas N Ferraro
Journal:  Epilepsy Behav       Date:  2017-06-23       Impact factor: 2.937

Review 2.  Epileptogenesis.

Authors:  Asla Pitkänen; Katarzyna Lukasiuk; F Edward Dudek; Kevin J Staley
Journal:  Cold Spring Harb Perspect Med       Date:  2015-09-18       Impact factor: 6.915

Review 3.  What non-neuronal mechanisms should be studied to understand epileptic seizures?

Authors:  Damir Janigro; Matthew C Walker
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

4.  Protective Role of UCP2 in Oxidative Stress and Apoptosis during the Silent Phase of an Experimental Model of Epilepsy Induced by Pilocarpine.

Authors:  Marina Rascio Henriques Dutra; Regiane Dos Santos Feliciano; Kalil Ribeiro Jacinto; Telma Luciana Furtado Gouveia; Eduardo Brigidio; Andrey Jorge Serra; Mariana Morris; Maria da Graça Naffah-Mazzacoratti; José Antônio Silva
Journal:  Oxid Med Cell Longev       Date:  2018-08-06       Impact factor: 6.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.